Regeneron Pharmaceuticals (NQ:REGN)

735.20 +0.39 (+0.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

July 17, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

All three can be bought on the dip.

Via The Motley Fool

Topics Intellectual Property

Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

July 16, 2026

From Robbins LLP

Via Business Wire

1 Large-Cap Stock with Exciting Potential and 2 We Turn Down

July 14, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Via StockStory

REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals ↗

June 12, 2026

Via Chartmill

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗

July 02, 2026

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Via The Motley Fool

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗

July 01, 2026

It might pull it off, provided several things fall right in place.

Via The Motley Fool

Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗

June 29, 2026

Via Chartmill

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗

June 27, 2026

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

Via The Motley Fool

Topics Initial Public Offering

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

June 25, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Underrated Weight Loss Stocks to Buy and Hold ↗

June 23, 2026

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Via The Motley Fool

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

June 22, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

This Stock Is Up 58% This Year. Is It too Late to Buy? ↗

June 17, 2026

There could be additional catalysts for this drugmaker over the next year.

Via The Motley Fool

3 Profitable Stocks We Think Twice About

June 17, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

June 10, 2026

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

June 09, 2026

From Pomerantz LLP

Via GlobeNewswire

Top S&P500 movers in Monday's session ↗

June 08, 2026

Via Chartmill

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

June 04, 2026

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Why Regeneron (REGN) Stock Is Trading Up Today

June 03, 2026

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the afternoon session after the company announced an expanded cancer therapy ...

Via StockStory

2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky

June 03, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Via StockStory

Topics Stocks

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

June 02, 2026

From Pomerantz LLP

Via GlobeNewswire

3 Nasdaq 100 Stocks We Find Risky

June 01, 2026

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...

Via StockStory

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

May 28, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN): Grabar Law Office is Investigating Claims on Your

May 27, 2026

From Grabar Law Office

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

May 26, 2026

From Pomerantz LLP

Via GlobeNewswire

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗

May 26, 2026

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.

Via The Motley Fool

Topics Regulatory Compliance

Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Grabar Law Office is Investigating Claims on

May 26, 2026

From Grabar Law Office

Via GlobeNewswire

Amylyx Stock: Why the Full Pipeline Story Matters ↗

May 24, 2026

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

Via MarketBeat

Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron

May 22, 2026

Check out the companies making headlines this week: Toll Brothers (NYSE:TOL): Homebuilding company Toll Brothers (NYSE:TOL) rose by 8.3% on Wednesday after t...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.